ERBB2 and nail disorder: However, the present study suggests that skin and subcutaneous tissue disorders, especially nail disorders, are more strongly associated with lapatinib based on the detection algorithms, which aligns with a recent pharmacovigilance study on HER-2 inhibitors (Tang et al., 2025).